Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02997111 · ClinicalTrials.gov registry record · NA
PFA-100 Responsive to Effect of Energy Drinks on Platelet Function
A NA study of Thrombosis and Platelet Function, sponsored by St. Louis University.
- Completed
- Registry status
- NA
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT02997111: Completed NA study of Thrombosis and Platelet Function, sponsored by St. Louis University.
NCT02997111 is a NA study of Thrombosis and Platelet Function that has completed, run by St. Louis University. The registered enrollment target is 13 participants, below the 470-participant average among 28 other Thrombosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02997111, a NA study of Thrombosis and Platelet Function, has completed, sponsored by St. Louis University.
- COMPLETED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the responsiveness of the Platelet Function Analyzer (PFA-100) to the effect of energy drinks on platelet function. Participants' will have blood drawn prior to and 60 minutes after ingesting 250ml of a commercially available sugar-free energy drink.
Primary Outcome
Agonist induced platelet activation and aggregation resulting in occlusion of the aperture and cessation of blood flow termed the closure time
Conditions Studied
Interventions
- DEVICE PFA-100
Study Locations (1)
Missouri
- Saint Louis University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2017-02-14 |
| Est. Completion | 2017-06-20 |
| Phase | NA |
What the finished NCT02997111 record still lists
NCT02997111 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 470-participant average among 28 other Thrombosis trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Thrombosis appearing as the primary indexed condition, and to 1 intervention - of which PFA-100 is the first listed.
NCT02997111 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT02997111 about?
NCT02997111 is a clinical study titled "PFA-100 Responsive to Effect of Energy Drinks on Platelet Function". This study evaluates the responsiveness of the Platelet Function Analyzer (PFA-100) to the effect of energy drinks on platelet function. Participants' will have blood drawn prior to and 60 minutes after ingesting 250ml of a commercially available sugar-free energy drink.
What is the current status of trial NCT02997111?
This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2017-02-14. Estimated completion is 2017-06-20.
What conditions does trial NCT02997111 study?
This clinical trial studies the following conditions: Thrombosis, Platelet Function.
What interventions are being tested in trial NCT02997111?
The interventions under investigation include: PFA-100 (DEVICE).
Who is sponsoring clinical trial NCT02997111?
This trial is sponsored by St. Louis University, which has 107 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02997111 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02997111's enrollment target sits among peer trials
13 25th of 28 higher than 4 of 28 other Thrombosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thrombosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neonatal Platelet Transfusion Threshold Trial
RECRUITING · NA
-
Impact of Prophylactic Low-molecular Weight Heparin Dosing on Clotting Parameters Following Cesarean Delivery
COMPLETED · NA
-
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RECRUITING
-
Positron Emission Tomography (PET) Imaging of Thrombosis
RECRUITING · Phase 1
-
Pharmacogenomics of Warfarin in Hispanics and Latinos
RECRUITING
-
Vascular Lab Resource (VLR) Biorepository
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI